<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112796">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634854</url>
  </required_header>
  <id_info>
    <org_study_id>120660</org_study_id>
    <nct_id>NCT01634854</nct_id>
  </id_info>
  <brief_title>A Study Comparing Vaginal Misoprostol and Intravenous Oxytocin for Induction of Labor</brief_title>
  <official_title>Randomized Comparison of Vaginal Misoprostol and Intravenous Oxytocin for Labor Induction in Multiparous Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effectiveness of vaginal misoprostol (Cytotec) and intravenous
      oxytocin (Pitocin) in multiparous women who present at term for labor induction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both oxytocin and misoprostol have been demonstrated to be safe and effective methods for
      induction of labor. A direct comparison of efficacy and time to delivery in multiparas has
      not been specifically investigated. Additionally, the study will look at costs of the two
      drugs.Oxytocin is administered through an IV so requires more direct patient care time from
      the Registered Nurse, IV pump, and tubing, whereas misoprostol is a tablet, administered
      only once, per vagina or orally, every 4 hours. Misoprostol is also very inexpensive
      comparatively; if equally or more efficacious than oxytocin, this could demonstrate quite a
      cost and time savings to Vanderbilt University Medical Center and other institutions. Safety
      of either drug is not in question.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from induction to vaginal delivery</measure>
    <time_frame>Time to delivery in hours and minutes from initiation of medication</time_frame>
    <description>Comparing the time to delivery in multiparas undergoing induction of labor with vaginal misoprostol or intravenous oxytocin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal and neonatal morbidity</measure>
    <time_frame>Through discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal satisfaction with labor</measure>
    <time_frame>6 weeks post-partum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excessive uterine activity necessitating treatment</measure>
    <time_frame>Measured from initiation of medication until delivery time</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Induction of Labor in Multiparous Women</condition>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal Misoprostol</intervention_name>
    <description>Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal</description>
    <arm_group_label>Vaginal Misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Oxytocin</intervention_name>
    <description>Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.
Route of administration: intravenous</description>
    <arm_group_label>Intravenous Oxytocin</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical candidate for labor induction utilizing either misoprostol or oxytocin

          -  Greater than or equal to 18 years of age

          -  Multiparous

          -  Singleton gestation;

          -  Greater than 37 weeks gestation;

          -  Cephalic presentation

        Exclusion Criteria:

          -  Any clinical contraindication to misoprostol as induction drug

          -  Age less than 18 years

          -  Contraindication to vaginal birth

          -  Nonreassuring fetal heart rate tracing

          -  Prior uterine surgery

          -  Active labor

          -  Active maternal bleeding

          -  Chorioamnionitis (infection)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Wilson-Liverman, MSN, CNM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chaudhuri S, Mitra SN, Banerjee PK, Biswas PK, Bhattacharyya S. Comparison of vaginal misoprostol tablets and prostaglandin E2 gel for the induction of labor in premature rupture of membranes at term: a randomized comparative trial. J Obstet Gynaecol Res. 2011 Nov;37(11):1564-71. doi: 10.1111/j.1447-0756.2011.01575.x. Epub 2011 Jun 16.</citation>
    <PMID>21676083</PMID>
  </reference>
  <reference>
    <citation>Olagbuji BN, Ezeanochie MC, Kubeyinje W, Dunsin T, Ande AB. Pregnancy outcome following induction of labor with intravaginal misoprostol for decreased fetal movements at term. J Matern Fetal Neonatal Med. 2011 Oct;24(10):1225-7. doi: 10.3109/14767058.2011.572309. Epub 2011 Apr 20.</citation>
    <PMID>21506657</PMID>
  </reference>
  <reference>
    <citation>Saeed GA, Fakhar S, Nisar N, Alam AY. Misoprostol for term labor induction: a randomized controlled trial. Taiwan J Obstet Gynecol. 2011 Mar;50(1):15-9. doi: 10.1016/j.tjog.2009.08.001.</citation>
    <PMID>21482368</PMID>
  </reference>
  <reference>
    <citation>Shakya R, Shrestha J, Thapa P. Safety and efficacy of misoprostol and dinoprostone as cervical ripening agents. JNMA J Nepal Med Assoc. 2010 Jan-Mar;49(177):33-7.</citation>
    <PMID>21180218</PMID>
  </reference>
  <reference>
    <citation>Hofmeyr GJ, Gülmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2010 Oct 6;(10):CD000941. doi: 10.1002/14651858.CD000941.pub2. Review.</citation>
    <PMID>20927722</PMID>
  </reference>
  <reference>
    <citation>Crane JM, Butler B, Young DC, Hannah ME. Misoprostol compared with prostaglandin E2 for labour induction in women at term with intact membranes and unfavourable cervix: a systematic review. BJOG. 2006 Dec;113(12):1366-76. Review.</citation>
    <PMID>17081181</PMID>
  </reference>
  <reference>
    <citation>Lin MG, Nuthalapaty FS, Carver AR, Case AS, Ramsey PS. Misoprostol for labor induction in women with term premature rupture of membranes: a meta-analysis. Obstet Gynecol. 2005 Sep;106(3):593-601.</citation>
    <PMID>16135593</PMID>
  </reference>
  <reference>
    <citation>Li XM, Wan J, Xu CF, Zhang Y, Fang L, Shi ZJ, Li K. Misoprostol in labour induction of term pregnancy: a meta-analysis. Chin Med J (Engl). 2004 Mar;117(3):449-52. Review.</citation>
    <PMID>15043790</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 9, 2014</lastchanged_date>
  <firstreceived_date>July 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Angela Wilson-Liverman</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
